Yerevan
Tbilisi
Moscow
Paris
Los Angeles
Beijing
English
Հայերեն Русский
Main Timeline Video Share
May the Holiday Warm Hearts: Idram and IDBank Support the Children of Heroes Beneficiaries of the "By Your Side" program at IDBank AraratBank Named Large CSR Company of the Year Idram Joins the Fight Against Food Insecurity Ucom’s Renovated Sales and Service Center in Yerevan Mall Reopens 1% idcoin instead of New Year’s suffering: practical tips Idram Junior Donated Books to Schools Big Christmas Market with Idram, IDBank and idplus Ucom Supports Wildlife Monitoring in Ararat Region IDBank, Idram, and idplus at the Big Christmas Market Converse Bank Deputy CEO and CFO, Grant Akopian, Elected to BACEE Board Ucom and SunChild NGO Install a Solar Plant in Alaverdi Kindergarten
Timeline
AraratBank Participates in “Women’s Empowerment Principles in Armenia” Conference Unibank’s Perpetual Bonds Were Acquired in Nearly One Day Acba bank and France’s Proparco to continue strengthening their long-term strategic partnershipTeam Holding Announces the Launch of Bond Placement. Underwriter - Freedom Broker Armenia Unibank Issues the First in Armenia Perpetual Bonds Team Holding Announces the Launch of Bond Placement. Underwriter - Freedom Broker Armenia AraratBank Joins Armenia's New Greening Initiative: 100 Hectares of New Forest within Three YearsApply for a Unibank salary card and get a chance to win 1 000 000 AMDEuromoney Names Ameriabank Armenia’s Best Bank for Real Estate for the Second Year in a Row S&P Global Ratings has assigned IDBank CJSC a long-term rating of “BB-” and a short-term rating of “B” with a “stable” prospectAn unprecedented Evening for the Armenian Fashion and Hospitality Industry: World-Renowned Dress Designer Jacob Meyer Presents His Masterpieces at the ONE&ONLY Antigravity Theatre in The Dvin HotelA Brand-New Section on Idram&IDBankSeveral real and profitable offers ahead of Black Friday: IDBank and IdramAraratBank Joins Social Impact Award 2025 Summit in LjubljanaIDBank issued the 1st tranche of bonds of 2026Ucom Supports the Development of Space Engineering in Armenia Prioritizing Information Security: IDBank and Idram Support APOCALYPSE CTF 2025IDBank's Representative, Innesa Amirbekyan Appointed Co-Chair of the ICC Banking Commission Task Force on GuaranteesUcom General Director Ralph Yirikian Awards Certificates to Participants of Cybersecurity Training Course Acba and Proparco mark one year of partnership, strengthening rural financing and Armenias’s economic resilience
All Timeline »
Life
echo '
';

1 in 4 people face side effects after getting COVID-19 vaccine

One in four people experiences side effects after being vaccinated against coronavirus. These are mostly minor side effects like pain at the injection site or headache, Lancet Infectious Diseases reported.

Analysis of data from the ZOE COVID Symptom Study, conducted by researchers at King's College London, found that side effects in the general population after vaccination with Pfizer and AstraZeneca were much lower than those reported in the trials.

The study also reported a significant reduction in infection rates from 12 to 21 days after the first dose of Pfizer (58% reduction) and AstraZeneca (39% reduction) compared to controls. The reduction in infection at least 21 days after the first dose is 69% for Pfizer and 60% for AstraZeneca.

Research has shown that:

  • 25.4% of vaccinated people reported one or more systemic side effects, while 66.2% reported one or more local side effects.
  • 13.5% of participants reported side effects after the first dose of Pfizer, 22.0% after the second dose of Pfizer, and 33.7% after the first dose of AstraZeneca.
  • The most common systemic side effect was a headache. 7.8% of people reported headaches after the first dose of Pfizer and 13.2% after the second dose of Pfizer. 22.8% of people who received the first dose of the AstraZeneca vaccine reported headaches.
  • The second most common systemic side effect was fatigue. 8.4% and 14.4% of participants reported fatigue after the first and second doses of the Pfizer vaccine, and 21.1% reported fatigue after the first dose of the AstraZeneca vaccine.
  • The most common localized side effect was soreness: 57.2% and 50.9% after the first and second doses of Pfizer vaccine and 49.3% after the first dose of AstraZeneca vaccine.

Side effects were more common in people under the age of 55 and in women.